[ORGANIZATION]
Irccs Istituto Auxologico Italiano
Featured in 1 tracked story · first seen
Situations
Mavacamten efficacy and oHCM diagnosis updates
4 clusters · 14 sources · last updated
Latest: FDA approves mavacamten for adolescents with obstructive HCM
Bristol Myers Squibb presented long-term data from the Explorer-Lte study at the European Society of Cardiology Congress in Munich. The results indicate that mavacamten, a cardiac myosin inhibitor, maintains its benefits